Intellia Therapeutics

Intellia Therapeutics is a clinical-stage biotechnology company pioneering the development of potentially curative therapeutics using CRISPR-based genome editing technologies. Founded in 2014 by leading scientists in the field, including Nobel laureates Jennifer Doudna and Emmanuelle Charpentier, the company aims to treat severe diseases by precisely editing genes within the human body. Its integrated platform spans both in vivo and ex vivo applications, with a pipeline focused on genetic diseases, oncology, and autoimmune conditions. Headquartered in the biotech hub of Cambridge, Massachusetts, it is considered a leader in translating CRISPR gene editing from laboratory discovery into human medicines.

Company overview

Intellia Therapeutics was established in 2014, capitalizing on the groundbreaking discovery of the CRISPR-Cas9 system for genome editing. The company's scientific founders include pioneers Jennifer Doudna of the University of California, Berkeley, Emmanuelle Charpentier, then at the Umeå University, Luciano Marraffini of The Rockefeller University, and Rodolphe Barrangou of North Carolina State University. Intellia is led by President and Chief Executive Officer John Leonard, a veteran of the pharmaceutical industry with experience at companies like AbbVie. The company maintains its headquarters and research laboratories in Cambridge, Massachusetts, leveraging the region's dense ecosystem of academic institutions like the Massachusetts Institute of Technology and Harvard University, as well as venture capital firms. Its mission is to develop one-time, curative treatments for patients with life-threatening genetic disorders, building on the foundational intellectual property from its founders and strategic partners like Caribou Biosciences.

Technology and platform

Intellia's core technology is based on a modular genome editing platform that utilizes CRISPR-Cas9 and other CRISPR systems, such as CRISPR-Cas12a. A key innovation is its proprietary lipid nanoparticle delivery technology, which enables the targeted delivery of CRISPR components, specifically guide RNA and messenger RNA encoding the Cas9 nuclease, to specific tissues like the liver after intravenous administration. This in vivo approach allows for precise editing of disease-causing genes directly within a patient's body. Complementing this, the company also employs ex vivo strategies where patient cells, such as T cells or hematopoietic stem cells, are edited outside the body before being reinfused. The platform is designed for versatility, aiming to achieve diverse genetic modifications including gene knockout, targeted insertion, and base editing to address a wide array of molecular defects underlying genetic diseases.

Clinical pipeline and programs

Intellia's clinical pipeline features several investigational therapies, with its most advanced programs targeting the liver. NTLA-2001, for the treatment of hereditary transthyretin amyloidosis with polyneuropathy, is a landmark in vivo CRISPR therapy and has reported positive interim results from ongoing Phase 1 and Phase 3 studies. Another in vivo candidate, NTLA-2002, targets hereditary angioedema by knocking out the KLKB1 gene. In the ex vivo domain, NTLA-5001 is an investigational WT1-targeted T cell receptor therapy for acute myeloid leukemia. The pipeline also includes earlier-stage research programs in areas like alpha-1 antitrypsin deficiency, hemophilia, and autoimmune diseases, showcasing the breadth of its platform. These programs are conducted under regulatory oversight from agencies like the U.S. Food and Drug Administration and the European Medicines Agency.

Collaborations and partnerships

Strategic alliances are central to Intellia's business and development strategy. Its foundational partnership with Regeneron Pharmaceuticals, established in 2016, is a broad collaboration focused on discovering and developing in vivo CRISPR therapies for a wide range of diseases, with Regeneron providing significant funding and co-development support. Intellia also has a multi-target research collaboration with Novartis to develop engineered cell therapies for sickle cell disease and other hematological diseases. Furthermore, the company maintains a strategic relationship with Caribou Biosciences, co-founded by Jennifer Doudna, which provides access to foundational CRISPR-Cas9 intellectual property. These partnerships with major pharmaceutical companies provide not only financial resources but also shared expertise in drug development, manufacturing, and global commercialization.

Financials and corporate milestones

Intellia completed its initial public offering on the NASDAQ stock exchange under the ticker symbol NTLA in 2016, raising capital to fund its research. The company's financial resources are derived from equity financings, payments from its collaborations with partners like Regeneron Pharmaceuticals and Novartis, and investment from entities like the Canada Pension Plan Investment Board. Major corporate milestones include the first-ever administration of a systemically delivered CRISPR therapy inside the human body in 2020, the initiation of its pivotal Phase 3 study for NTLA-2001, and the expansion of its manufacturing capabilities. As a pre-commercial company, it incurs significant research and development expenses as it advances its clinical programs, with its valuation and investor interest heavily tied to clinical data readouts and regulatory progress from its lead candidates.

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:CRISPR Category:Companies listed on NASDAQ